SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.380
-0.100 (-2.87%)
Jun 3, 2026, 1:57 PM EDT - Market open
SAB Biotherapeutics Market Cap
SAB Biotherapeutics has a market cap or net worth of $237.53 million as of June 3, 2026. Its market cap has increased by 1,281.83% in one year.
Market Cap
237.53M
Enterprise Value
139.12M
1-Year Change
1,281.83%
Ranking
Category
Stock Price
$3.38
Market Cap Chart
Since February 9, 2021, SAB Biotherapeutics's market cap has increased from $130.75M to $237.53M, an increase of 81.66%. That is a compound annual growth rate of 11.89%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 2, 2026 | 244.56M | 37.35% |
| Dec 31, 2025 | 178.05M | 408.46% |
| Dec 31, 2024 | 35.02M | -44.79% |
| Dec 29, 2023 | 63.43M | 113.36% |
| Dec 30, 2022 | 29.73M | -91.24% |
| Dec 31, 2021 | 339.54M | 159.68% |
| Feb 9, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Adagene | 250.75M |
| Entrada Therapeutics | 248.99M |
| AC Immune | 244.03M |
| Codexis | 242.69M |
| ALX Oncology Holdings | 242.21M |
| Coherus Oncology | 242.17M |
| Caribou Biosciences | 241.01M |
| Cybin | 234.67M |